Clinical Trial Update: A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers. [Phase 1]

View source ↗

Summary

Phase I study evaluating safety and immunogenicity of a recombinant MVA vaccine encoding antigen 85A for tuberculosis, delivered intradermally in healthy volunt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• MVA-A85A vaccine (recombinant Modified Vaccinia Ankara encoding Antigen 85A)

Snippet

Sponsor: University of Oxford | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED